BCL2scan: Biochemical ligand binding assays for anti-apoptotic BCL2 family members

Eurofins DiscoverX has developed a best in class comprehensive panel of quantitative biochemical ligand binding assays for anti-apoptotic BCL2 family proteins that can be used to identify and to optimize therapeutic small molecule inhibitors targeting proteins from this target class. The BCL2 family of proteins determine the commitment of cells to apoptosis and are emerging therapeutic targets for oncology, auto-immune disease, neurodegeneration, and aging-related morbidities. The BCL2 family consists of pro-apoptotic and anti-apoptotic members that interact to regulate the MOMP pathway to apoptosis. The anti-apoptotic family members are the focus of many drug discovery efforts and include BCL2, BCLXL, BCLW, BCL2A1 and MCL1.
 
The Eurofins DiscoverX BCL2 family assays enable measurement of potency and selectivity across these anti-apoptotic family members. You can screen, profile and measure Kd values in one flexible format in both high or low-throughput modes.